CHAMPIONS ONCOLOGY, INC. (CSBR) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-07-31..
Gross margin
Overview →Financial period ending 2026-07-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-07-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 60.66M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | 30.44M USD | Cost of Goods and Services Sold |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-07-31 | (m) | $60.66M | $30.44M | (m) |
| 2026-04-30 | (m) | $59.42M | $30.90M | (m) |
| 2026-01-31 | (m) | $57.95M | $31.36M | (m) |
| 2025-10-31 | (m) | $58.42M | $29.15M | (m) |
| 2025-07-31 | (m) | $56.88M | $29.31M | (m) |
| 2025-04-30 | (m) | $56.94M | $28.39M | (m) |
| 2025-01-31 | (m) | $58.59M | $28.37M | (m) |
| 2024-10-31 | (m) | $53.57M | $29.60M | (m) |
| 2024-07-31 | (m) | $51.66M | $28.79M | (m) |
| 2024-04-30 | (m) | $50.16M | $29.40M | (m) |
| 2024-01-31 | (m) | $49.22M | $29.49M | (m) |
| 2023-10-31 | (m) | $49.98M | $29.34M | (m) |
| 2023-07-31 | (m) | $52.69M | $30.16M | (m) |
| 2023-04-30 | (m) | $53.87M | $29.53M | (m) |
| 2023-01-31 | (m) | $53.68M | $28.41M | (m) |
| 2022-10-31 | (m) | $54.10M | $27.12M | (m) |
| 2022-07-31 | (m) | $51.60M | $25.29M | (m) |
| 2022-04-30 | (m) | $49.11M | $23.63M | (m) |
| 2022-01-31 | (m) | $46.80M | $23.25M | (m) |
| 2021-10-31 | (m) | $44.41M | $21.47M | (m) |
| 2021-07-31 | (m) | $42.75M | $21.51M | (m) |
| 2021-04-30 | (m) | $41.04M | $21.45M | (m) |
| 2021-01-31 | (m) | $39.22M | (m) | (m) |
| 2020-10-31 | (m) | $37.42M | (m) | (m) |
| 2020-07-31 | (m) | $34.93M | (m) | (m) |
| 2020-04-30 | (m) | $32.12M | (m) | (m) |
| 2020-01-31 | (m) | $31.09M | (m) | (m) |
| 2019-10-31 | (m) | (m) | (m) | (m) |
| 2019-07-31 | (m) | $27.58M | (m) | (m) |
| 2019-04-30 | (m) | $27.07M | (m) | (m) |
| 2019-01-31 | (m) | (m) | (m) | (m) |
| 2018-07-31 | (m) | (m) | (m) | (m) |
| 2018-04-30 | (m) | $20.24M | (m) | (m) |
| 2017-07-31 | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |